<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510870</url>
  </required_header>
  <id_info>
    <org_study_id>FI028.DEX001.2019</org_study_id>
    <secondary_id>2019-002040-24</secondary_id>
    <secondary_id>KLnro136/2019</secondary_id>
    <nct_id>NCT04510870</nct_id>
  </id_info>
  <brief_title>Iron Deficiency as an Ignored Cause of Infertility</brief_title>
  <acronym>IDI</acronym>
  <official_title>Iron Deficiency as an Ignored Cause of Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dextra Fertility Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dextra Fertility Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency may play a critical role in human infertility, oocyte quality and may even&#xD;
      play a role in endometrial receptivity. By correcting iron deficiency, low ferritin values,&#xD;
      in infertile women with intravenous iron supplementation, embryo quality and pregnancy rates&#xD;
      may improve.&#xD;
&#xD;
      The main objective is to evaluate the effect of intravenous iron supplementation on embryo&#xD;
      quality (number of good quality blastocysts).&#xD;
&#xD;
      Randomized, double blind, parallel group, cross-over study of ferric carboxymaltose compared&#xD;
      to placebo (NaCl infusion).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 17, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of good quality blastocysts</measure>
    <time_frame>day 5-7 after oocyte pick up</time_frame>
    <description>good quality blastocyst are defined as blastocyst, which are transferable or may be frozen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blastulation rate</measure>
    <time_frame>day 5-7 after oocyte pick up</time_frame>
    <description>number of blastocysts /fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy/ pregnancy rate</measure>
    <time_frame>10 weeks after oocyte pick up,at oocyte pick up it counted to be 2 weeks of gestation.</time_frame>
    <description>ongoing pregnancy at 12 weeks of gestation/ positive pregnancy test (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mature oocyte rate</measure>
    <time_frame>1 day after oocyte pick up</time_frame>
    <description>number of mature oocytes / total number of oocytes (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>1 day after oocyte pick up</time_frame>
    <description>number of fertilized oocytes/total number of oocytes (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
    <description>number of attached embryos/ embryo transfer (%)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>1 month after infusion, at the time of embryo transfer</time_frame>
    <description>difference of endometrial thickness in mm compared at the day of infusion and the day of embryo transfer</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Iron Deficiency</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)&#xD;
infusion is NaCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion is NaCl&#xD;
infusion is ferric carboxymaltose, dosage according to the summary of product characteristics (SmPC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose Injection</intervention_name>
    <description>Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>NaCl infusion group</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl infusion</intervention_name>
    <description>Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>NaCl infusion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient's 18 to 42 years and in full consent&#xD;
&#xD;
          -  Ferritin â‰¤ 30 ug/l&#xD;
&#xD;
          -  Anti-mullerian hormone (AMH) &gt; 1ug/l&#xD;
&#xD;
          -  Planned for IVF/ ICSI treatment&#xD;
&#xD;
          -  Diagnosis for treatment: tubal factor, male factor or unexplained infertility (NUD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endometriosis&#xD;
&#xD;
          -  Poor responder&#xD;
&#xD;
          -  Inflammatory bowel disease (IBD), colitis ulcerosa&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Cardiac insufficiency&#xD;
&#xD;
          -  Body Mass Index (BMI) over 35&#xD;
&#xD;
          -  Known hypersensitivity to the active substance, to ferric carboxymaltose or any of its&#xD;
             excipients, or to other parental iron products&#xD;
&#xD;
          -  Clinical evidence of iron overload or disturbances in the utilization of iron&#xD;
&#xD;
          -  use of atosiban or filgrastim during stimulation or embryo transfer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>evaluates female part in reproduction</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annika Tulenheimo-Silfvast, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>senior consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annika Tulenheimo-Silfvast, M.D.</last_name>
    <phone>+358503507991</phone>
    <email>annika.tulenheimo-silfvast@fimnet.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niklas Simberg, Ass.prof.</last_name>
    <phone>+3584125152020</phone>
    <email>niklas.simberg@dextra.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dextra Fertility Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Annika Tulenheimo-Silfvast, M.D.</last_name>
      <phone>+358503507991</phone>
      <email>annika.tulenheimo-silfvast@dextra.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low ferritin</keyword>
  <keyword>infertility</keyword>
  <keyword>in vitro fertilization (IVF)</keyword>
  <keyword>intracytoplasmic sperm injection (ICSI)</keyword>
  <keyword>assisted reproductive technology (ART)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

